Author Affiliations: Statens Serum Institut, Copenhagen, Denmark (Dr Mølbak); and the Centers for Disease Control and Prevention, Atlanta, Ga (Drs Mead and Griffin).
Shiga toxin–producing Escherichia coli
O157:H7 is an important cause of enteric illness in developed countries.1 Infection typically presents as a diarrheal illness,
often with bloody stools. In approximately 8% of patients,2
infection progresses to hemolytic uremic syndrome (HUS), a life-threatening
condition characterized by microangiopathic hemolytic anemia, thrombocytopenia,
and renal failure.
Mølbak K, Mead PS, Griffin PM. Antimicrobial Therapy in Patients With Escherichia coli O157:H7 Infection. JAMA. 2002;288(8):1014-1016. doi:10.1001/jama.288.8.1014